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Text: Background and objective: In early stages of multiple sclerosis (MS) iron deposits within focal T2
lesions may be associated with the progression of the disease. The aim of this study is to evaluate
the association between iron deposit within new T2 lesions and some radiological and clinical
measurements in patients with clinically isolated syndrome (CIS).
Materials and methods: 17 patients (9 women; median age, 31 years; EDSS range, [0, 4.5]; mean
disease duration, 3.29 months) with CIS. Baseline and 12 months proton density (PD) and
T2-weighted, and susceptibility weighted (SW) sequences were acquired on a 3.0T MRI.
Iron content within new T2 lesions at month-12 (M12) MRI was measured on filtered-phase SW
images as the increase with regard to white matter values obtained from 17 healthy controls (15
women; median age, 35 years). Two regions of interest (ROI) were defined at M12 MRI: PD/T2 new
lesion mask (ROI-1), and region with high iron content (ROI-2) within ROI-1. The measurements
analyzed were: Fe increase per tissue gram in ROI-1 (iFe1M12) and in ROI-2 (iFe2M12) at M12,
number of pixels in ROI-2 (NPM12) at M12, number (NGdM12) and volume (VGdM12) of
gadolinium-enhanced lesions at M12, brain parenchymal fraction (BPFM12) at M12, number
(NNT2M12) and volume (VNT2M12) of new lesions at M12, the percentage of brain volume change
(PBVC) between baseline and M12, EDSS, and disease duration. Statistical analysis involved
Spearman rank correlation to test correlation between iron deposits and clinical and radiological
variables.
Results: Some correlations between measurements involving iron deposits and radiological
measurements were found (iFe2M12 vs. NNT2M12 [0.700, p=0.002]; NPM12 vs. NNT2M12 [0.808,
p< 0.001]; iFe2M12 vs. VNT2M12 [0.544, p=0.024]; NPM12 vs. VNT2M12 [0.886, p< 0.001]; NPM12
vs. NGdM12 [0.765, p< 0.001]; NPM12 vs. VGdM12 [0.757, p< 0.001]).
Conclusions: The results obtained suggest a strong association in CIS patients between the
presence of new T2 lesions and the extension or the level of abnormal iron deposits within them. The
extension of the high iron content region is also correlated to the presence of active lesions.
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